Abeona Therapeutics Inc. (NASDAQ:ABEO) Upgraded by BidaskClub to “Strong-Buy”

BidaskClub upgraded shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) from a buy rating to a strong-buy rating in a research note released on Wednesday morning.

Several other analysts also recently commented on ABEO. Zacks Investment Research downgraded shares of Abeona Therapeutics from a hold rating to a sell rating in a report on Tuesday, March 14th. FBR & Co reaffirmed a buy rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a report on Wednesday, April 5th. Maxim Group reaffirmed a buy rating and issued a $14.00 price objective on shares of Abeona Therapeutics in a report on Wednesday, April 12th. Jefferies Group LLC reaffirmed a buy rating and issued a $11.00 price objective on shares of Abeona Therapeutics in a report on Wednesday, April 26th. Finally, Cantor Fitzgerald reaffirmed a buy rating and issued a $21.00 price objective on shares of Abeona Therapeutics in a report on Friday, May 12th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $17.43.

Shares of Abeona Therapeutics (ABEO) opened at 8.90 on Wednesday. The stock’s 50 day moving average is $5.54 and its 200-day moving average is $5.24. Abeona Therapeutics has a 12-month low of $2.33 and a 12-month high of $9.85. The stock’s market cap is $358.27 million.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Thursday, May 18th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.02. The business had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.28 million. Abeona Therapeutics had a negative net margin of 2,568.57% and a negative return on equity of 26.99%. Equities analysts expect that Abeona Therapeutics will post ($0.56) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was first posted by Stock Observer and is the property of of Stock Observer. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.thestockobserver.com/2017/07/18/abeona-therapeutics-inc-nasdaqabeo-upgraded-by-bidaskclub-to-strong-buy.html.

Several institutional investors have recently bought and sold shares of ABEO. Highbridge Capital Management LLC boosted its position in Abeona Therapeutics by 23.5% in the first quarter. Highbridge Capital Management LLC now owns 681,611 shares of the biopharmaceutical company’s stock valued at $3,408,000 after buying an additional 129,811 shares in the last quarter. Wellington Management Group LLP boosted its position in Abeona Therapeutics by 17.4% in the first quarter. Wellington Management Group LLP now owns 204,590 shares of the biopharmaceutical company’s stock valued at $1,023,000 after buying an additional 30,300 shares in the last quarter. Geode Capital Management LLC boosted its position in Abeona Therapeutics by 2.4% in the first quarter. Geode Capital Management LLC now owns 196,073 shares of the biopharmaceutical company’s stock valued at $980,000 after buying an additional 4,588 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Abeona Therapeutics by 869.7% in the first quarter. Goldman Sachs Group Inc. now owns 116,000 shares of the biopharmaceutical company’s stock valued at $580,000 after buying an additional 104,038 shares in the last quarter. Finally, Laurion Capital Management LP purchased a new position in Abeona Therapeutics during the first quarter valued at about $277,000. Hedge funds and other institutional investors own 35.60% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply